See more : ESPIRE HOSPITALITY LIMITED (ESPIRE.BO) Income Statement Analysis – Financial Results
Complete financial analysis of CTI BioPharma Corp. (CTIC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CTI BioPharma Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- SHAOXING XINGXIN N (001358.SZ) Income Statement Analysis – Financial Results
- Krones AG (KRNNF) Income Statement Analysis – Financial Results
- ValOre Metals Corp. (KVLQF) Income Statement Analysis – Financial Results
- Century Plyboards (India) Limited (CENTURYPLY.BO) Income Statement Analysis – Financial Results
- Sartorius Aktiengesellschaft (SRT.DE) Income Statement Analysis – Financial Results
CTI BioPharma Corp. (CTIC)
About CTI BioPharma Corp.
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 53.95M | 0.00 | 0.00 | 3.35M | 26.29M | 25.15M | 57.41M | 16.12M | 60.08M | 34.68M | 0.00 | 0.00 | 319.00K | 80.00K | 11.43M | 127.00K | 80.00K | 16.09M | 29.59M | 24.77M | 16.90M | 6.24M | 502.04K | 100.00K | 13.20M | 11.80M | 9.10M |
| Cost of Revenue | 3.51M | 161.00K | 4.20M | 0.00 | 879.00K | 364.00K | 1.38M | 1.94M | 895.00K | 137.00K | 0.00 | 0.00 | 0.00 | 0.00 | 3.24M | 49.00K | 0.00 | 518.00K | 1.10M | 840.00K | 423.00K | 394.00K | -1.02M | -2.20M | -1.90M | -1.60M | 14.30M |
| Gross Profit | 50.43M | -161.00K | -4.20M | 3.35M | 25.41M | 24.78M | 56.03M | 14.18M | 59.18M | 34.54M | 0.00 | 0.00 | 319.00K | 80.00K | 8.19M | 78.00K | 80.00K | 15.57M | 28.49M | 23.93M | 16.47M | 5.84M | 1.53M | 2.30M | 15.10M | 13.40M | -5.20M |
| Gross Profit Ratio | 93.49% | 0.00% | 0.00% | 100.00% | 96.66% | 98.55% | 97.60% | 87.96% | 98.51% | 99.60% | 0.00% | 0.00% | 100.00% | 100.00% | 71.62% | 61.42% | 100.00% | 96.78% | 96.27% | 96.61% | 97.50% | 93.68% | 304.14% | 2,300.00% | 114.39% | 113.56% | -57.14% |
| Research & Development | 36.90M | 39.14M | 25.94M | 24.11M | 36.47M | 32.87M | 64.96M | 76.63M | 86.46M | 33.62M | 62.31M | 34.90M | 27.03M | 30.18M | 51.61M | 72.02M | 61.99M | 68.77M | 101.13M | 89.53M | 58.76M | 44.67M | 26.57M | 27.70M | 29.20M | 27.30M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 17.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 84.83M | 56.20M | 17.63M | 19.16M | 21.18M | 31.44M | 45.31M | 53.96M | 56.24M | 42.29M | 38.24M | 38.29M | 48.04M | 57.73M | 41.61M | 35.32M | 35.30M | 61.72M | 78.52M | 55.64M | 49.80M | 35.27M | 20.42M | 9.80M | 11.60M | 10.10M | 7.60M |
| Other Expenses | 8.51M | -161.00K | 4.20M | 1.32M | 0.00 | 0.00 | -5.08M | 253.00K | 2.72M | 155.00K | 30.05M | 0.00 | 0.00 | 0.00 | -7.79M | 913.00K | 792.00K | -69.96M | 2.29M | 1.34M | 6.70M | 9.39M | 10.43M | 2.20M | 1.90M | 1.60M | 1.80M |
| Operating Expenses | 130.23M | 95.33M | 47.77M | 43.26M | 57.65M | 64.30M | 105.19M | 130.84M | 145.42M | 75.91M | 100.55M | 73.19M | 75.07M | 87.90M | 85.44M | 108.25M | 98.09M | 60.53M | 181.94M | 146.51M | 115.26M | 89.33M | 57.43M | 39.70M | 42.70M | 39.00M | 9.40M |
| Cost & Expenses | 133.75M | 95.33M | 47.77M | 43.26M | 58.53M | 64.67M | 106.57M | 132.78M | 146.31M | 76.05M | 100.55M | 73.19M | 75.07M | 87.90M | 88.68M | 108.30M | 98.09M | 61.05M | 183.05M | 147.35M | 115.68M | 89.72M | 56.40M | 37.50M | 40.80M | 37.40M | 23.70M |
| Interest Income | 1.68M | 38.00K | 204.00K | 1.17M | 1.22M | 0.00 | -2.61M | -2.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.14M | 2.42M | 1.03M | 1.52M | 1.73M | 2.04M | 2.83M | 2.49M | 2.68M | 1.54M | 56.00K | 1.04M | 2.33M | 4.81M | 8.56M | 14.83M | 44.58M | 17.56M | 10.99M | 9.33M | 11.24M | 5.99M | 544.29K | 0.00 | 400.00K | 0.00 | 500.00K |
| Depreciation & Amortization | -56.00K | -161.00K | 204.00K | 3.29M | 593.00K | 717.00K | 831.00K | 990.00K | 1.10M | 1.57M | 2.35M | 2.41M | 1.84M | 1.77M | 5.23M | 4.69M | 6.50M | 10.28M | 11.43M | 8.44M | 14.24M | 12.24M | 10.43M | 2.20M | 1.90M | 1.60M | 1.80M |
| EBITDA | -79.85M | -95.33M | -47.77M | -37.43M | -32.90M | -39.52M | -49.16M | -116.67M | -86.23M | -39.63M | -98.97M | -58.91M | -74.76M | -81.56M | -77.28M | -132.99M | -98.60M | -57.73M | -229.88M | -112.27M | -98.79M | -62.05M | -40.95M | -34.10M | -22.70M | -21.40M | -11.60M |
| EBITDA Ratio | -148.02% | 0.00% | 0.00% | -1,118.83% | -102.67% | -150.79% | -84.23% | -719.40% | -149.13% | -114.29% | 0.00% | 0.00% | -24,597.49% | -111,022.50% | -1,454.18% | -93,375.59% | -105,916.25% | -464.01% | -776.77% | -453.32% | -144.55% | -995.00% | -8,156.98% | -34,100.00% | -171.97% | -181.36% | -127.47% |
| Operating Income | -79.80M | -95.33M | -47.77M | -40.71M | -32.90M | -39.52M | -49.16M | -116.67M | -86.23M | -41.53M | -101.50M | -62.19M | -74.76M | -81.56M | -77.28M | -132.99M | -98.60M | -57.73M | -240.83M | -122.59M | -98.79M | -83.49M | -55.90M | -37.40M | -27.60M | -25.60M | -14.60M |
| Operating Income Ratio | -147.91% | 0.00% | 0.00% | -1,217.07% | -125.14% | -157.16% | -85.64% | -723.91% | -143.54% | -119.75% | 0.00% | 0.00% | -23,434.17% | -101,948.75% | -676.02% | -104,713.39% | -123,250.00% | -358.77% | -813.77% | -494.99% | -584.68% | -1,338.76% | -11,134.98% | -37,400.00% | -209.09% | -216.95% | -160.44% |
| Total Other Income/Expenses | -13.20M | -2.58M | -4.68M | 688.00K | 3.55M | -1.31M | -3.79M | -4.10M | -8.00M | -2.02M | -190.00K | -429.00K | -20.64M | -13.84M | -102.75M | -5.12M | -37.22M | -44.77M | -11.47M | -7.45M | 48.88M | 9.20M | 4.52M | 1.70M | 3.00M | 2.90M | 1.20M |
| Income Before Tax | -92.99M | -97.91M | -52.45M | -40.02M | -29.35M | -40.83M | -52.95M | -120.76M | -94.23M | -43.55M | -101.69M | -62.62M | -95.40M | -95.40M | -180.03M | -138.11M | -135.82M | -102.51M | -252.30M | -130.03M | -49.90M | -74.29M | -51.38M | -35.70M | -24.60M | -22.70M | -13.40M |
| Income Before Tax Ratio | -172.37% | 0.00% | 0.00% | -1,196.50% | -111.65% | -162.38% | -92.24% | -749.34% | -156.85% | -125.58% | 0.00% | 0.00% | -29,904.39% | -119,243.75% | -1,574.78% | -108,746.46% | -169,773.75% | -636.99% | -852.53% | -525.06% | -295.35% | -1,191.23% | -10,235.12% | -35,700.00% | -186.36% | -192.37% | -147.25% |
| Income Tax Expense | -1.95M | 1.73M | 500.00K | 2.29M | 5.28M | 723.00K | -963.00K | -1.60M | -5.32M | -485.00K | -134.00K | 609.00K | -3.41M | 1.79M | -85.79M | -362.00K | 51.35M | 48.78M | -76.87M | 11.21M | 71.36M | 15.19M | 5.06M | 1.70M | 3.40M | 2.90M | 1.70M |
| Net Income | -91.04M | -99.64M | -52.95M | -42.32M | -29.32M | -40.67M | -52.01M | -119.42M | -93.37M | -42.74M | -101.37M | -62.36M | -82.64M | -95.40M | -180.03M | -138.11M | -135.82M | -102.51M | -252.30M | -130.03M | -49.90M | -80.27M | -51.93M | -36.30M | -25.00M | -23.00M | -13.90M |
| Net Income Ratio | -168.76% | 0.00% | 0.00% | -1,265.08% | -111.53% | -161.74% | -90.60% | -741.02% | -155.41% | -123.26% | 0.00% | 0.00% | -25,906.58% | -119,243.75% | -1,574.78% | -108,746.46% | -169,773.75% | -636.99% | -852.53% | -525.06% | -295.35% | -1,287.25% | -10,343.54% | -36,300.00% | -189.39% | -194.92% | -152.75% |
| EPS | -0.79 | -1.11 | -0.74 | -0.73 | -0.52 | -1.12 | -1.86 | -4.26 | -6.29 | -3.74 | -17.44 | -18.18 | -36.21 | -62.44 | -1.86K | -9.15K | -14.52K | -19.06K | -56.02K | -46.71K | -17.74K | -28.49K | -24.59K | -28.03K | -19.47K | -17.95K | -12.81K |
| EPS Diluted | -0.79 | -1.11 | -0.74 | -0.73 | -0.52 | -1.12 | -1.86 | -4.26 | -6.29 | -3.74 | -17.44 | -18.18 | -36.21 | -62.44 | -1.86K | -9.15K | -14.52K | -19.06K | -56.02K | -46.71K | -17.74K | -28.49K | -24.59K | -28.03K | -19.47K | -17.95K | -12.81K |
| Weighted Avg Shares Out | 114.69M | 90.12M | 71.14M | 57.97M | 56.07M | 36.45M | 27.95M | 28.05M | 14.85M | 11.42M | 5.81M | 3.43M | 2.28M | 1.53M | 96.56K | 15.10K | 9.36K | 5.38K | 4.50K | 2.78K | 2.81K | 2.82K | 2.11K | 1.30K | 1.28K | 1.28K | 1.09K |
| Weighted Avg Shares Out (Dil) | 114.69M | 90.12M | 71.14M | 57.97M | 56.07M | 36.45M | 27.95M | 28.05M | 14.85M | 11.42M | 5.81M | 3.43M | 2.28M | 1.53M | 96.56K | 15.10K | 9.36K | 5.38K | 4.50K | 2.78K | 2.81K | 2.82K | 2.11K | 1.30K | 1.28K | 1.28K | 1.09K |
Has CTI BioPharma (CTIC) Outpaced Other Medical Stocks This Year?
Here is how CTI BioPharma (CTIC) and Esperion Therapeutics (ESPR) have performed compared to their sector so far this year.
CTI BioPharma Presents New Anemia Benefit Data from Pacritinib Program at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition
SEATTLE , Dec. 11, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced an oral presentation and two poster presentations from the Company's pacritinib program at the 64th American Society of Hematology (ASH®) Annual Meeting and Exposition, taking place...
CTI BioPharma Corp. (CTIC) Q3 2022 Results - Earnings Call Transcript
CTI BioPharma Corp. (NASDAQ:CTIC ) Q3 2022 Results Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Adam Craig - President, Chief Executive Officer and Interim Chief Medical Officer James Fong - Executive Vice President and Chief Commercial...
CTI BioPharma (CTIC) Reports Q3 Loss, Tops Revenue Estimates
CTI BioPharma (CTIC) delivered earnings and revenue surprises of 13.33% and 0.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
CTI BioPharma Reports Third Quarter 2022 Financial Results
– VONJO® (pacritinib) net product revenue of $18.2 million in the third quarter, a 48% increase compared to the second quarter – – Increase in sales reflects strong growth in new patient starts – – Oral presentation of new data...
CTI BioPharma Announces Oral Presentation at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition
SEATTLE , Nov. 3, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced an oral presentation and two poster presentations from the Company's pacritinib program at the 64th American Society of Hematology (ASH®) Annual Meeting and Exposition, taking place in...
Best Penny Stocks To Buy? 4 To Watch Before November
Penny stocks to watch before November 2022 The post Best Penny Stocks To Buy? 4 To Watch Before November appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why CTI BioPharma Stock Crushed the Market Today
Simultaneous double thumbs-ups from a pair of pundits gave it boost.
Why CTI BioPharma Stock Withered on Wednesday
Investors didn't exactly cheer the latest prognosticator move on the company's shares.
CTI BioPharma Announces Presentation of New Anemia Benefit Data from Pacritinib Program at the Society of Hematologic Oncology (SOHO) Tenth Annual Meeting
SEATTLE , Sept. 21, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced two poster presentations from the Company's pacritinib program at the Society of Hematologic Oncology (SOHO) Tenth Annual Meeting, to be held in Houston, Texas and virtually...
Source: https://incomestatements.info
Category: Stock Reports